GT Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by GT Biopharma, Inc. (GTBP) on June 8, 2026. The Company is a Delaware corporation with its common stock registered on The Nasdaq Stock Market LLC. As of July 1, 2024, the Company operates as a fully remote entity without a physical principal executive office.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance amendments rather than financial performance.
Material Changes
On June 8, 2026, the Board of Directors approved an amendment to the Company's Amended and Restated Bylaws regarding the quorum requirement for stockholder meetings:
- Prior Requirement: A majority of outstanding shares entitled to vote was required to establish a quorum.
- New Requirement: The presence of holders of not less than one-third (1/3) of outstanding shares entitled to vote will now constitute a quorum.
- Rationale: The change addresses the increasing difficulty in obtaining a majority quorum due to brokerage firms opting out of discretionary or proportionate voting of shares held in street name.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. The primary risk addressed is the operational risk of failing to achieve a quorum for stockholder meetings, which the amendment aims to mitigate.
Key Facts for Investor Verification
- Verify the full text of Amendment No. 1 to the Amended and Restated Bylaws attached as Exhibit 3.1.
- Confirm the effective date of the quorum reduction is June 8, 2026.
- Note that the Company remains fully remote with no physical principal executive office.